| Literature DB >> 26502874 |
J S Sabirova1,2, J-P Hernalsteens2, S De Backer1, B B Xavier1, P Moons1, A Turlej-Rogacka1, H De Greve3,4, H Goossens1, S Malhotra-Kumar5.
Abstract
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA)-USA300 is notorious for its ability to cause community- and healthcare-acquired infections, which are even more difficult to treat when associated with a biofilm phenotype. We aimed to characterize the genetic determinants of biofilm formation in a USA300 skin abscess isolate (UAS391) that formed prolific biofilms.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26502874 PMCID: PMC4623894 DOI: 10.1186/s12864-015-1956-8
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Strains and plasmids used for clonal, genomic, and phenotypic analyses during this study
| Strains/Plasmids | Description | Source |
|---|---|---|
| Strains | ||
| UA S391 |
| [ |
| JE2 |
| NARSAa |
| FPR3757 |
| NARSA |
| TCH1516 |
| ATCC |
| UA S391-Erys | Heat-cured erythromycin-sensitive derive of UAS391 | This study |
| TCH1516-Erys | Heat-cured erythromycin-sensitive derive of TCH1516 | This study |
| UA S391-NE229 | UA S391-Erys transductant with mutation in EX97_05885 | This study |
| TCH1516-NE229 | TCH1516-Erys transductant with mutation in USA 300Hou_1162 | This study |
| NE229-pHD954 |
| This study |
| NE229-pHD957 |
| This study |
| UA S391-pHD957 |
| This study |
| RN0451 | Phage Φ11 lysogenic | NARSA |
| RN0450 |
| NARSA |
| RN4220 | Restriction-deficient intermediate | NARSA |
| Restriction-deficient intermediate | NARSA | |
| NE1646 | Transposon mutant with insertion in USA200HOU_0155 (SA USA300_0145) | NARSA |
| NE229 | Transpos on mutant with insertion in USA300HOU_1162 (SA USA300_1119) | NARSA |
| NE1081 | Transpo on mutant with insertion in USA300HOU_2626 (SA USA300_2561) | NARSA |
| NE454 | Transpo on mutant with insertion in USA300HOU_2631 (SA USA300_2566) | NARSA |
| NE1290 | Transposon mutant with insertion USA300HOU_2641 (SA USA300_2576) | NARSA |
| NE81 | Transposon mutant with insertion in USA300HOU_2319 (SA USA300_2285) | NARSA |
| NE1036 | Transposon mutant with insertion in USA300HOU_2602 (SA USA300_2542) | NARSA |
| NE1038 | Transposon mutant with insertion in USA300HOU_2678 (SA USA300_2610) | NARSA |
| NE33 | Transposon mutant with insertion in USA300HOU_2654 (SA USA300_2589) | NARSA |
| NE1262 | Transposon mutant with insertion in USA300HOU_2026 (SA USA300_1984) | NARSA |
| NE1875 | Transposon mutant with insertion in USA300HOU_1934 (SA USA300_1918) | NARSA |
| NE1 | Transposon mutant with insertion in USA300HOU_1372 (SaA USA300_1327) | NARSA |
| NE334 | Transposon mutant with insertion in USA300HOU_2197 (SA USA300_2161) | NARSA |
| NE809 | Transposon mutant with insertion in USA300HOU_1260 (SA USA300_1214) | NARSA |
| NE1403 | Transposon mutant with insertion in USA300HOU_1260 (SA USA300_1585) | NARSA |
| NE1026 | Transposon mutant with insertion in USA 300HOU_1338 (SA USA 300_1298) | NARSA |
| NE1314 | Transposon mutant with insertion in USA300HOU_0953(SA USA300_0896) | NARSA |
| Plasmids | ||
| pALC2073 | Shuttle vector pALC2073 | [ |
| pHD954 | pALC2073 with cloned | This study |
| pHD957 | pALC2073 with cloned | This study |
aThis library now exists at www.beiresources.org and is discussed by Fey et al. [8]
Fig. 1Whole genome maps of USA300 strains. Green lines indicate identity of restriction pattern among the maps and red horizontal marks represent the variations
Fig. 2Biofilm formation of USA300 strains in the dynamic shear flow assay. Quantification (a) and visualization (b) of biofilms formed by wild-type USA300 strains and corresponding derivate strains
Single nucleotide polymorphisms (SNPs) between TCH1516/FPR3757 and UAS391. Consensus base represents TCH1516 and FPR3757, allele represents a corresponding base in UAS391. Predicted amino acid changes in UAS391 compared to TCH1516 and FPR3757 were not displayed for synonymous SNPs
| Consensus base (TCH1516/FPR3757) | Allele UAS391 | Gene locus tag (in TCH1516/FPR3757) | Predicted amino acid change (TCH1516/FPR3757) | Gene and putative function |
|---|---|---|---|---|
| G | T | USA300HOU_0286/SAUSA300_0267 | Leu1Phe | IS1272 transposase |
| T | C | USA300HOU_0155/SAUSA300_0145 | Phosphate-import protein PhnD/ABC Transporter, periplasmic binding protein | |
| G | A | USA300HOU_0521/SAUSA300_0513 | Met386Ile |
|
| A | C | USA300HOU_1051/SAUSA300_1013 | Asn267Thr/Asn263Thr | Bacterial cell division membrane protein FtsW |
| A | G | USA300HOU_1162/SAUSA300_1119 | Glu524Gly |
|
| G | T | USA300HOU_1166/SAUSA300_1123 | Gly169Val |
|
| A | G | USA300HOU_1372/SAUSA300_1327 | Val1114Ala | Ebh: Cell Wall-Associated Fibronectin-Binding Protein |
| C | A | USA300HOU_2197/SAUSA300_2161 | Hyaluronate lyase is a glycosaminoglycan (GAG) polysaccharide lyase family. This family consists of a group of secreted bacterial lyase enzymes capable of acting on glycosaminoglycans, such as hyaluronan and chondroitin, in the extracellular matrix of host tissues, contributing to the invasive capacity of the pathogen. | |
| G | A | USA300HOU_2631/SAUSA300_2566 | Pro27Ser | HTH-type Transcriptional regulator ArcR, signal transduction system |
| C | T | USA300HOU_2641/SAUSA300_2576 | PTS system, fructose-specific II ABC component, multi protein system involved in regulation of metabolic and transcriptional process | |
| T | C | USA300HOU_2319/SAUSA300_2285 | Aldose 1-epimerase | |
| G | A | USA300HOU_2602/SAUSA300_2542 | Arg517* 1 | Acyl-coenzyme A synthetases/AMP-(fatty) acid ligases (Lipid metabolism) |
| A | C | USA300HOU_2654/SAUSA300_2589 | Ser1782Ala | Serine-rich adhesin for platelets, cell surface protein precursor; KxYKxGKxW signal peptide |
| C | T | USA300HOU_0502/SAUSA300_0486 | Thr85Met | Uncharacterized protein YabR |
| C | T | USA300HOU_1626/SAUSA300_1585 | Ser35Leu | tRNA threonylcarbamoyladenosine dehydratase (Cells lacking this gene have a normal growth phenotype, but are unable to survive in a competitive growth situation with the wild-type strain. They display only the t6A but not the ct6A modification in tRNAs, and have lower decoding efficiency than wild-type. They show no defects in antibiotic sensitivity. In growth competition experiments, a |
| A | G | USA300HOU_2026/SAUSA300_1984 | Lys118Arg | Putative membrane peptidase YdiL |
| T | C | USA300HOU_1488/SAUSA300_1436 | phage lipoprotein | |
| T | - | USA300HOU_1338/SAUSA300_1298 | Phe130fs2 | 5-bromo-4-chloroindolyl phosphate hydrolysis protein |
1The symbol (*) refers to the predicted amino acid change as a stopcodon caused by the corresponding SNP
2The abbreviation (fs) refers to ‘frame shift mutation’
Fig. 3Biofilm formation of USA300 strains in the dynamic shear flow assay. Quantification (a) and visualization (b) of biofilms formed by JE2 and its transposon mutants
Fig. 4Transcription levels of the fakA gene in UAS391, TCH1516, FPR3757, JE2 and in corresponding transductant strains. Transcription levels of fakA were measured in duplicate by real-time RT-PCR and expressed as an amplification plot and Ct mean values